24
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Long COVID-19 may be defined as patients who, four weeks after the diagnosis of SARS-Cov-2 infection, continue to have signs and symptoms not explainable by other causes. The estimated frequency is around 10% and signs and symptoms may last for months. The main long-term manifestations observed in other coronaviruses (Severe Acute Respiratory Syndrome (SARS), Middle East respiratory syndrome (MERS)) are very similar to and have clear clinical parallels with SARS-CoV-2: mainly respiratory, musculoskeletal, and neuropsychiatric. The growing number of patients worldwide will have an impact on health systems. Therefore, the main objective of these clinical practice guidelines is to identify patients with signs and symptoms of long COVID-19 in primary care through a protocolized diagnostic process that studies possible etiologies and establishes an accurate differential diagnosis. The guidelines have been developed pragmatically by compiling the few studies published so far on long COVID-19, editorials and expert opinions, press releases, and the authors’ clinical experience. Patients with long COVID-19 should be managed using structured primary care visits based on the time from diagnosis of SARS-CoV-2 infection. Based on the current limited evidence, disease management of long COVID-19 signs and symptoms will require a holistic, longitudinal follow up in primary care, multidisciplinary rehabilitation services, and the empowerment of affected patient groups.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Characteristics of Coronavirus Disease 2019 in China

          Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. Methods We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. Results The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. Conclusions During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

            There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Remdesivir for the Treatment of Covid-19 — Final Report

              Abstract Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. Results A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). Conclusions Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.)
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Int J Environ Res Public Health
                Int J Environ Res Public Health
                ijerph
                International Journal of Environmental Research and Public Health
                MDPI
                1661-7827
                1660-4601
                20 April 2021
                April 2021
                : 18
                : 8
                : 4350
                Affiliations
                [1 ]Permanent Board of the Catalan Society of Family and Community Medicine (CAMFiC), 08009 Barcelona, Spain; lconangla.mn.ics@ 123456gencat.cat (L.C.F.); jordimestres@ 123456camfic.org (J.M.)
                [2 ]Primary Care Centre Les Corts, Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE), 08028 Barcelona, Spain; badriyan@ 123456clinic.cat
                [3 ]Primary Healthcare Transversal Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
                [4 ]Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, 08036 Barcelona, Spain; mbritozeron@ 123456gmail.com (P.B.-Z.); mramos@ 123456clinic.cat (M.R.-C.)
                [5 ]Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA-Sanitas, 08034 Barcelona, Spain
                [6 ]Department of Autoimmune Diseases, ICMiD, Hospital Clínic, 08036 Barcelona, Spain
                [7 ]Department of Statistics and Operations Research, Universitat Politècnica de Catalunya (UPC), 08034 Barcelona, Spain
                [8 ]Jaume I Health Centre, Institut Català de la Salut, Universitat Rovira i Virgili, 43005 Tarragona, Spain; Anamaria.moragas@ 123456urv.cat
                [9 ]College of Catalan Physicians, 08017 Barcelona, Spain; jaume.sellares@ 123456comb.cat
                [10 ]Permanent Board of the Spanish Society of Family and Community Medicine (semFYC), 08009 Barcelona, Spain; ggalindoo@ 123456semfyc.es
                [11 ]Board of Spanish Society of Managers of Primary Care (SEDAP), 28026 Madrid, Spain; dr.rmorera@ 123456gmail.com
                [12 ]IDIAP Jordi Gol, 08007 Barcelona, Spain; jbasora@ 123456idiapjgol.org
                [13 ]Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain; ATRILLA@ 123456clinic.cat
                Author notes
                [* ]Correspondence: ASISO@ 123456clinic.cat
                [†]

                ANNEX. Members of the CAMFiC long COVID-19 Study Group: Alarcón Belmonte I; Also Fontanet A; Barrot de la Fuente J; Brotons Cuixart C; Burdoy Joaquin E; Caballol Angelats R; Cabré Vila JJ; Cantero Gómez FX; Carbonell Abella C; Carrillo Muñoz R; Casasa Plana A; Copetti Fanlo S; Cots Yago JM; Deniel Rosanas J; Díez-Cascón P; Ferrer-Vidal Cortella D; Fernández Pérez J; Franch Nadal J; Guirado Vila P; Hoyo J; Lozano Fernández JJ; Limón Ramírez E; Llor Vila C; Martin Luján F; Martin Álvarez R; Mas Heredia M; Mascort Roca J; Montero Alia JJ; Moreno Escrivà S; Ortega Vila Y; Perelló Bratescu A; Sans Corrales M; Sequeira Aymar E; Serrano Manzano M; Serrano-Pons J; Solà Gonfaus M; Solanes Cabús M; Veganzones Guanyabens I; Vilaseca Llobet JM; Villafàfila Ferrero R; Vinyoles Bargalló E.

                Author information
                https://orcid.org/0000-0002-6102-3033
                https://orcid.org/0000-0002-1307-0943
                https://orcid.org/0000-0001-5709-6734
                Article
                ijerph-18-04350
                10.3390/ijerph18084350
                8073248
                33923972
                57d6dc58-2013-4d05-9209-d4cbca38e73a
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 19 February 2021
                : 16 April 2021
                Categories
                Review

                Public health
                sars-cov-2,primary care,long covid-19
                Public health
                sars-cov-2, primary care, long covid-19

                Comments

                Comment on this article